All In Biotech

Drug Trial Radar · NCT03889249

Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke

Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke: QuICR & OPTIMISE Registry Based Pragmatic Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: May 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,600

Actual

Start

Dec 10, 2019

Primary completion

Apr 26, 2022

Study completion Apr 30, 2023

Sponsor

Lead sponsor
University of CalgaryAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The proposed trial is a pragmatic, registry linked, prospective, randomized (1:1) controlled, open-label parallel group clinical trial with blinded endpoint assessment of 1600 patients to test if intravenous tenecteplase (0.25 mg/kg body weight, max dose 25 mg) is non-inferior to intravenous alteplase (0.9 mg/kg body weight) in patients with acute ischemic stroke otherwise eligible for intravenous thrombolysis as per standard care. All patients will have standard of care medical management on an acute stroke unit. There are no additional trial specific management recommendations. Patients will be followed for approximately 90-120 days.

Conditions

  • Stroke, Acute
  • Thromboses, Intracranial

Interventions

  • TenecteplaseDrug

    Stroke Thrombolytic

  • AlteplaseDrug

    Stroke Thrombolytic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Rankin Scale (mRS) 0-1 (freedom from disability)Time frame: By telephone Follow-up between 90-120 days

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • University of Calgary

    Calgary, Alberta, Canada

  • Grey Nuns Hospital

    Edmonton, Alberta, Canada

  • University of Alberta

    Edmonton, Alberta, Canada

  • Medicine Hat Regional Hospital

    Medicine Hat, Alberta, Canada

  • Red Deer Regional Hospital

    Red Deer, Alberta, Canada

  • Kelowna General Hospital

    Kelowna, B.C., Canada

  • Royal Columbian Hospital

    New Westminster, British Columbia, Canada

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

  • University of Manitoba

    Winnipeg, Manitoba, Canada

  • Halifax Infirmary Queen Elizabeth II

    Halifax, Nova Scotia, Canada

  • Hamilton Health Sciences General Hospital

    Hamilton, Ontario, Canada

  • Kingston Health Science Centre

    Kingston, Ontario, Canada

  • London Health Sciences

    London, Ontario, Canada

  • Ottawa Civic Hospital

    Ottawa, Ontario, Canada

  • St. Michaels Hospital

    Toronto, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Toronto Western Hospital

    Toronto, Ontario, Canada

  • Queen Elizabeth Hospital

    Charlottetown, Prince Edward Island, Canada

  • CHUM -Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, Canada

  • Univerisite Laval-Hopital de l'Enfant-Jesus

    Québec, Quebec, Canada

  • Universite de Sherbrooke

    Sherbrooke, Quebec, Canada

  • Royal University Hospital

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.